
Paving the Way for Innovation
Dr. Christopher Flowers is passionate about working as a team and sharing with others the same enthusiasm for medicine that he has had since the onset of his career.

Dr. Christopher Flowers is passionate about working as a team and sharing with others the same enthusiasm for medicine that he has had since the onset of his career.

Chike Springer was many things — a husband, son, brother, uncle and patriot — but he was most known for his positivity and determination.

Loncastuximab tesirine-lpyl is the first and only CD-19-directed antibody drug conjugate single agent approved for relapsed/refractory diffuse large B-cell lymphoma (DLBCL).

As the rollout of the new COVID-19 vaccines continues, there is constant new data related to the vaccines and their effects on individuals. While most of this data is preliminary, information related to the efficacy and effect of the vaccine…

Transformed lymphoma occurs when an indolent lymphoma turns into a more aggressive one. A transformation occurs when genetic changes in the indolent lymphoma cells cause them to begin growing faster and behaving more aggressively. Lymphoma Research Foundation Grantee Raphael Eric…

World-renowned hematologist/oncologist receives inaugural award for outstanding commitment in the field of mantle cell lymphoma research and patient care.

There are several chemotherapy and targeted anticancer drugs approved or under investigation for the treatment of lymphoma. Unlike traditional chemotherapy that is administered intravenously (IV) in a hospital or clinic, oral therapies are administered via a pill, taken at home…

Investment supports early-career scientists dedicated to developing patient therapies and lymphoma cures.
Thousands to Raise Awareness and Funds through Virtual Celebration and Socially Distanced Neighborhood Walks The Lymphoma Research Foundation (LRF) will offer Walk On! America, a twist on its Spring 2021 Team LRF Lymphoma Walks to bring the lymphoma community together safely in the time of COVID-19. Lymphoma…

Axicabtagene ciloeucel has been approved for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).